Elucirem shortage — ES supply status & alternatives

Elucirem

—

In supply · Australia

In supply · 🇦🇺 Australia · short in🇪🇸 ES

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Registrations on file
Active ingredient (INN)	Elucirem
Therapeutic category	Auto-created by Agencia Española de Medicamentos — Problemas de Suministro scraper
Controlled substance	No
Marketing-authorisation holders	GUERBET, Guerbet LLC

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇪🇸

Spain

AEMPS · 2d ago

High

Verified timeline regulator events

🇪🇸 17 May 2026

high reported

🇪🇸 23 Feb 2026

high reported

Sources official regulators

🇪🇸

AEMPS

verified 2d ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders2 registrations · 2 MA holders

Product	Strength	Form	Market	MA holder	Status
Elucirem	—	—	🌐 EU	GUERBET	Active
ELUCIREM	485.1mg/mL	injection	🇺🇸 US	Guerbet LLC	Active

Mederti Drug Report

Generated 4 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.